论文部分内容阅读
目的：探讨α-连环素（α－catenin，α－cat）在非小细胞肺癌（NSCLC）中的表达情况及其临床意义。方法：采用链霉抗生物素蛋白-过氧化物酶（S-P）免疫组化法检测71例NSCLC手术标本α-cat表达。结果：肺癌标本α－cat表达异常形式包括异位表达和阴性。56．3％（40／71）肺癌标本α－cat表达异常，包括16．9％（12／71）异位表达和39．4％（28／71）阴性。伴有淋巴结转移的NSCLC标本中，α－cat表达异常占70％（28／40），包括25％（10／40）异位表达、45％（18／40）阴性。无淋巴结转移组仅有38．7％（12／31）α－cat表达异常，其中异位表达6．4％（2／31）、阴性32.3％（10／31），α－cat表达异常与淋巴结转移相差非常显著（P＜0．01）。不同分化程度NSCLC中，α-cat表达异常的频率在低、中和高分化组分别为66．7％、65．2％、20％（P<0．01）。结论：肺癌组织中普遍存在α－cat表达异常。α－cat表达异常与NSCLC的淋巴结转移及组织分化程度相差显著。α－cat表达异常可能通过抑制细胞分化和促进淋巴结转移而影响NSCLC的临床进展。
Objective: To investigate the expression of α-catenin (α-cate) in non-small cell lung cancer (NSCLC) and its clinical significance. Methods: The expression of α-cat in 71 specimens of NSCLC was detected by streptavidin-peroxidase (S-P) immunohistochemistry. Results: Abnormal expression of α-cat in lung cancer specimens included ectopic expression and negative. Abnormal expression of α-cat was detected in 56.3% (40/71) lung cancer specimens, including 16.9% (12/71) ectopic expression and 39.4% (28/71) negative. In NSCLC specimens with lymph node metastasis, abnormal expression of α-cat accounted for 70% (28/40), including 25% (10/40) ectopic expression and 45% (18/40) negative. In the group with no lymph node metastasis, only 38.7% (12/31) of the α-cat expression was abnormal. The ectopic expression was 6.4% (2/31) and the negative was 32.3% (10/31). The expression of α-cat was abnormal. The difference in lymph node metastasis was very significant (P < 0.01). The frequency of abnormal expression of α-cat in different differentiation NSCLC was 66.7%, 65.2% and 20% respectively in the low, moderate and well-differentiated groups (P<0.01). Conclusion: Abnormal expression of α-cat is common in lung cancer tissues. Abnormal expression of α-cat and lymph node metastasis and differentiation of NSCLC were significantly different. Abnormal expression of α-cat may affect the clinical progress of NSCLC by inhibiting cell differentiation and promoting lymph node metastasis.